XENE Valuation
Xenon Pharmaceuticals Inc
$
30.300
- Overview
- Forecast
- Valuation
- Earnings
XENE Relative Valuation
XENE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XENE is overvalued; if below, it's undervalued.
Historical Valuation
Xenon Pharmaceuticals Inc (XENE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.06. The fair price of Xenon Pharmaceuticals Inc (XENE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 30.30 USD , Xenon Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：30.30
Fair
Undervalued
-7.22
PE
1Y
3Y
5Y
Trailing
Forward
-4.99
EV/EBITDA
Xenon Pharmaceuticals Inc. (XENE) has a current EV/EBITDA of -4.99. The 5-year average EV/EBITDA is -6.67. The thresholds are as follows: Strongly Undervalued below -15.29, Undervalued between -15.29 and -10.98, Fairly Valued between -2.36 and -10.98, Overvalued between -2.36 and 1.95, and Strongly Overvalued above 1.95. The current Forward EV/EBITDA of -4.99 falls within the Historic Trend Line -Fairly Valued range.
-4.61
EV/EBIT
Xenon Pharmaceuticals Inc. (XENE) has a current EV/EBIT of -4.61. The 5-year average EV/EBIT is -7.79. The thresholds are as follows: Strongly Undervalued below -12.55, Undervalued between -12.55 and -10.17, Fairly Valued between -5.42 and -10.17, Overvalued between -5.42 and -3.04, and Strongly Overvalued above -3.04. The current Forward EV/EBIT of -4.61 falls within the Overvalued range.
0.00
PS
Xenon Pharmaceuticals Inc. (XENE) has a current PS of 0.00. The 5-year average PS is 2109.18. The thresholds are as follows: Strongly Undervalued below -5163.57, Undervalued between -5163.57 and -1527.19, Fairly Valued between 5745.56 and -1527.19, Overvalued between 5745.56 and 9381.93, and Strongly Overvalued above 9381.93. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-9.04
P/OCF
Xenon Pharmaceuticals Inc. (XENE) has a current P/OCF of -9.04. The 5-year average P/OCF is -13.65. The thresholds are as follows: Strongly Undervalued below -20.00, Undervalued between -20.00 and -16.83, Fairly Valued between -10.48 and -16.83, Overvalued between -10.48 and -7.30, and Strongly Overvalued above -7.30. The current Forward P/OCF of -9.04 falls within the Overvalued range.
-7.87
P/FCF
Xenon Pharmaceuticals Inc. (XENE) has a current P/FCF of -7.87. The 5-year average P/FCF is -13.66. The thresholds are as follows: Strongly Undervalued below -22.20, Undervalued between -22.20 and -17.93, Fairly Valued between -9.38 and -17.93, Overvalued between -9.38 and -5.11, and Strongly Overvalued above -5.11. The current Forward P/FCF of -7.87 falls within the Overvalued range.
Xenon Pharmaceuticals Inc (XENE) has a current Price-to-Book (P/B) ratio of 3.30. Compared to its 3-year average P/B ratio of 3.50 , the current P/B ratio is approximately -5.92% higher. Relative to its 5-year average P/B ratio of 3.33, the current P/B ratio is about -1.11% higher. Xenon Pharmaceuticals Inc (XENE) has a Forward Free Cash Flow (FCF) yield of approximately -8.40%. Compared to its 3-year average FCF yield of -5.19%, the current FCF yield is approximately 61.69% lower. Relative to its 5-year average FCF yield of -5.34% , the current FCF yield is about 57.11% lower.
3.30
P/B
Median3y
3.50
Median5y
3.33
-8.40
FCF Yield
Median3y
-5.19
Median5y
-5.34
Competitors Valuation Multiple
The average P/S ratio for XENE's competitors is 29.98, providing a benchmark for relative valuation. Xenon Pharmaceuticals Inc Corp (XENE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XENE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XENE in the past 1 year is driven by Unknown.
People Also Watch
HBI
HanesBrands Inc
4.580
USD
0.00%
UGP
Ultrapar Participacoes SA
3.000
USD
+1.69%
HCC
Warrior Met Coal Inc
57.020
USD
-1.69%
ACAD
ACADIA Pharmaceuticals Inc
23.250
USD
+0.87%
DEI
Douglas Emmett Inc
15.550
USD
+0.32%
PLMR
Palomar Holdings Inc
132.520
USD
+0.57%
VSCO
Victoria's Secret & Co
21.480
USD
+3.22%
VCEL
Vericel Corp
40.120
USD
+1.01%
TDC
Teradata Corp
22.060
USD
+2.08%
TDW
Tidewater Inc
51.890
USD
+0.14%
FAQ
Is Xenon Pharmaceuticals Inc (XENE) currently overvalued or undervalued?
Xenon Pharmaceuticals Inc (XENE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.06. The fair price of Xenon Pharmaceuticals Inc (XENE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 30.30 USD , Xenon Pharmaceuticals Inc is Undervalued By Fair .
What is Xenon Pharmaceuticals Inc (XENE) fair value?
How does XENE's valuation metrics compare to the industry average?
What is the current P/B ratio for Xenon Pharmaceuticals Inc (XENE) as of Jul 28 2025?
What is the current FCF Yield for Xenon Pharmaceuticals Inc (XENE) as of Jul 28 2025?
What is the current Forward P/E ratio for Xenon Pharmaceuticals Inc (XENE) as of Jul 28 2025?